CST: 05/12/2016 12:31:53   

Plandai Biotechnology, Inc. Receives Initial Order From Coyne Healthcare

265 Days ago

ph²(TM) Product to Be Shipped by Mid April

LONDON, UNITED KINGDOM--(Marketwired - Mar 15, 2016) -  Plandaí Biotechnology, Inc. (OTC PINK: PLPL) ("Plandaí" or "the Company"), biopharmaceutical producer of the highly bioavailable Phytofare® catechin complex, today announced that it has received an initial order for 500,000 capsules of the Company's Pheroid® entrapped Phytofare® catechin complex -- trade named "ph²™" from Coyne Healthcare, leading developer of high-quality nutraceutical and food supplements based in South Africa. Plandaí previously announced that it had entered into a license and supply agreement with Coyne Healthcare to develop a new biopharmaceutical product using ph2TM under which Plandaí will prepare the capsules for Coyne who will then bottle, package and sell the product. Coyne Healthcare indicated that this initial order will be sold exclusively in South Africa but their intention is to expand the product internationally in the future.

The new Coyne Healthcare product represents the first application of ph²™ in a commercial product intended for human use. ph2™ is the combination of the nano-entrapment system, Pheroid®, with the Company's Phytofare® catechin complex. Pheroid® encapsulates, or entraps, the Phytofare® in a colloidal emulsion which clinical tests have shown both improves absorption into the blood plasma and protects the Phytofare® against metabolization during the digestive process. 

Callum Cottrell-Duffield, Vice President of Plandaí, commented, "This first order from Coyne Healthcare represents a milestone for Plandaí since it launches ph2 as a new, commercially viable product. Since we first executed the license agreement with North West University to use Pheroid® in human use, we've been working to build nutriceutical applications. ph2™ contains all eight catechins which are protected by the Pheroid® until they reach the blood stream. Clinical testing has shown that, when entrapped in Pheroid®, the bioavailability increases an additional 30% over our already high levels while also extending the residency of the antioxidants in the bloodstream at therapeutic levels over 24 hours."

Kevin Coyne, Managing Director of Coyne Healthcare, added, "We expect our new product to be enthusiastically received by the market place once they understand the superiority of the extract which has been clinically proven to deliver much higher levels of antioxidants. Green Tea has thousands of studies supporting its various health benefits, we can now deliver Green Tea like never before, and this is the new benchmark in supplementation. We're excited to be launching this breakthrough in South Africa as its home market and soon thereafter expanding internationally".

Founded in Cape Town, South Africa, Coyne Healthcare has been both developing and distributing high quality nutraceutical and food supplements since 2013. For additional information, visit: www.coynehealthcare.co.za

About Plandaí Biotechnology, Inc.
Plandaí Biotechnology, Inc. and its subsidiaries develop highly phyto-available™ extracts. Plandaí Biotechnology controls every aspect of the process, from growing the raw materials on its farms in South Africa, to producing its proprietary Phytofare® extracts in-house, allowing the Company to guarantee the continuity of supply as well as quality control throughout the entire process. Targeted industries for the Company's products include beverage, cosmeceutical, wellness, nutriceutical, anti-aging, and pharmaceutical. For more information, please visit http://www.plandaibiotech.com.

Safe Harbor Statement
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance or guarantee that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to: adverse economic conditions, competition, adverse federal, state and local government regulation, international governmental regulation, inadequate capital, inability to carry out research, development and commercialization plans, loss or retirement of key executives and other specific risks. To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made. Readers are advised to review our filings with the Securities and Exchange Commission that can be accessed over the Internet at the SEC's website located at http://www.sec.gov.

Plandai Biotechnology, Inc.
Hannah Merrill
(917) 900-6829